Answers are grounded in this paper and cite their sources.
In patients with progressive fibrosing interstitial lung diseases, the annual rate of decline in the FVC was significantly lower among patients who received nintedanib than among those who received placebo. Diarrhea was a common adverse event. (Funded by Boehringer Ingelheim; INBUILD ClinicalTrials.gov number, NCT02999178.).
No takes yet. Share an insight, caveat, or question.
Flaherty et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: